eXoZymes (NASDAQ:EXOZ) Posts Quarterly Earnings Results

eXoZymes (NASDAQ:EXOZ) announced its earnings results on Friday. The company reported ($0.24) EPS for the quarter, FiscalAI reports.

eXoZymes Stock Performance

EXOZ stock traded down $0.17 during midday trading on Friday, hitting $3.83. The company’s stock had a trading volume of 20,062 shares, compared to its average volume of 13,604. The stock has a market cap of $35.62 million, a price-to-earnings ratio of -3.22 and a beta of 3.34. The company has a quick ratio of 3.81, a current ratio of 3.81 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average price is $5.15 and its 200 day moving average price is $7.44. eXoZymes has a 1 year low of $3.24 and a 1 year high of $16.90.

Institutional Investors Weigh In On eXoZymes

An institutional investor recently bought a new position in eXoZymes stock. BlackRock Inc. bought a new position in shares of eXoZymes Inc. (NASDAQ:EXOZ) during the second quarter, according to its most recent filing with the SEC. The fund bought 9,610 shares of the company’s stock, valued at approximately $81,000. BlackRock Inc. owned 0.10% of eXoZymes at the end of the most recent reporting period.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of eXoZymes in a report on Wednesday, August 26th. Zacks Research upgraded shares of eXoZymes to a “hold” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, eXoZymes presently has an average rating of “Reduce”.

eXoZymes Company Profile

eXoZymes is a biotechnology company focused on cell-free biomanufacturing. Its approach uses enzymes outside living cells to produce compounds, offering an alternative to conventional manufacturing methods. The company’s work centers on developing its biomanufacturing platform and applying it to the production of useful molecules. Publicly available information about specific commercial products, customer markets, geographic reach and company leadership is limited.